Personalized cancer treatment trial for advanced solid tumors
Part of Cancer clinical trials.
This trial tests whether using a personalized approach (matching your tumor's genetic profile to a targeted drug) can help people with advanced solid cancers live longer. It is for people whose cancer is not responding to standard treatments and who have a genetic change that can be targeted by an FDA-approved drug not usually used for their cancer type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer has spread (metastatic) or cannot be removed by surgery, and you are expected to live between 6 and 16 months because of it.
- You have had no more than 2 prior cancer treatments.
- Your tumor has a specific genetic change (biomarker) that can be targeted with an FDA-approved drug that is not the standard treatment for your cancer type.
- You are in generally good health (able to do daily activities) with no major organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether a personalized cancer treatment plan based on your tumor’s test results can help people with aggressive cancers that are hard to treat. It may be an option if standard treatments didn’t work, aren’t possible for you, or you have few treatment choices.
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
This trial tests whether tailoring treatment to your tumor's specific genetic makeup can help when standard treatments are no longer working. It may give you access to therapies that are more likely to work for your cancer.
This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.
This Phase 2 study uses a team review of your tumor’s gene test results to help match you with treatments you may benefit from. It’s designed for people whose tumor has specific gene changes that suggest sensitivity to available medicines or may involve inherited (germline) risk.
This trial tests a personalized mRNA cancer vaccine (RH125) for people with advanced solid tumors that have spread or cannot be removed by surgery. It may be an option if standard treatments have stopped working or are not suitable, and for some, it will be given with a PD-1 blocker.
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.